tiprankstipranks
Rezolute reports Q2 EPS (22c), consensus (26c)
PremiumThe FlyRezolute reports Q2 EPS (22c), consensus (26c)
1M ago
Rezolute’s Advancements in CHI Treatment and Strategic Positioning Justify Buy Rating with $14 Target
Premium
Ratings
Rezolute’s Advancements in CHI Treatment and Strategic Positioning Justify Buy Rating with $14 Target
2M ago
Promising Developments in Rezolute’s cHI Treatment Drive Buy Rating
Premium
Ratings
Promising Developments in Rezolute’s cHI Treatment Drive Buy Rating
2M ago
Rezolute Gains FDA Breakthrough Designation for Ersodetug
PremiumCompany AnnouncementsRezolute Gains FDA Breakthrough Designation for Ersodetug
3M ago
Rezolute receives BTD from FDA for ersodetug in treatment of hypoglycemia
Premium
The Fly
Rezolute receives BTD from FDA for ersodetug in treatment of hypoglycemia
3M ago
Rezolute reports inducement award under Nasdaq listing rule
Premium
The Fly
Rezolute reports inducement award under Nasdaq listing rule
4M ago
Rezolute reports Q1 EPS (22c), consensus (33c)
PremiumThe FlyRezolute reports Q1 EPS (22c), consensus (33c)
5M ago
RZLT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
RZLT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
5M ago
Rezolute initiated with an Outperform at Wedbush
Premium
The Fly
Rezolute initiated with an Outperform at Wedbush
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100